TY - JOUR
T1 - Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus
AU - Chung, Cecilia P.
AU - Oeser, Annette
AU - Raggi, Paolo
AU - Solus, Joseph F.
AU - Avalos, Ingrid
AU - Linton, MacRae F.
AU - Fazio, Sergio
AU - Michael Stein, C.
N1 - Funding Information:
Acknowledgments This study was supported by grants (HL04012, HL65082, and GM5M01-RR00095) from the National Institutes of Health and by a grant from the Lupus Foundation of America, Nashville Chapter. Dr. Ingrid Avalos is supported by a grant from the American College of Rheumatology.
PY - 2008
Y1 - 2008
N2 - Patients with systemic lupus erythematosus (SLE) have accelerated atherosclerosis, but the underlying mechanisms are unclear. The size and number of lipoprotein particles may be better predictors of atherosclerosis than conventional cholesterol measurements. We measured lipoprotein subclasses by nuclear magnetic resonance spectroscopy (NMR), coronary artery calcification by electron beam computed tomography, and insulin resistance by homeostasis model assessment in 105 patients with SLE and 77 control subjects. VLDL particles were larger (50.0 ± 8.5 versus 47.7 ± 8.5 nm, P = 0.01) and concentrations of large high-density lipoprotein (HDL) particles lower (10.1 ± 5.3 versus 11.3 ± 5.1 nmol/L, P = 0.03) in patients with SLE than controls. In patients with SLE, small LDL concentration was associated with body mass index (rho = 0.27), insulin resistance (rho = 0.34), C-reactive protein (CRP; rho = 0.30), and erythrocyte sedimentation rate (ESR; rho = 0.20); all P < 0.05. Large HDL concentration was inversely associated with insulin resistance (rho = -0.29), disease activity (rho = -0.23), and ESR (rho = -0.39); all P < 0.05. VLDL concentrations correlated with CRP (rho = 0.22), ESR (rho = 0.24), disease damage (rho = 0.20), and corticosteroid exposure (rho = 0.29); all P < 0.05. Neither the concentration of lipoprotein subclasses nor particle size was associated with coronary artery atherosclerosis. There were only minor differences in the NMR lipid profiles of patients with SLE and controls. Lipoprotein subclasses were associated with metabolic variables, inflammatory markers, and corticosteroid use but not with coronary artery atherosclerosis in SLE.
AB - Patients with systemic lupus erythematosus (SLE) have accelerated atherosclerosis, but the underlying mechanisms are unclear. The size and number of lipoprotein particles may be better predictors of atherosclerosis than conventional cholesterol measurements. We measured lipoprotein subclasses by nuclear magnetic resonance spectroscopy (NMR), coronary artery calcification by electron beam computed tomography, and insulin resistance by homeostasis model assessment in 105 patients with SLE and 77 control subjects. VLDL particles were larger (50.0 ± 8.5 versus 47.7 ± 8.5 nm, P = 0.01) and concentrations of large high-density lipoprotein (HDL) particles lower (10.1 ± 5.3 versus 11.3 ± 5.1 nmol/L, P = 0.03) in patients with SLE than controls. In patients with SLE, small LDL concentration was associated with body mass index (rho = 0.27), insulin resistance (rho = 0.34), C-reactive protein (CRP; rho = 0.30), and erythrocyte sedimentation rate (ESR; rho = 0.20); all P < 0.05. Large HDL concentration was inversely associated with insulin resistance (rho = -0.29), disease activity (rho = -0.23), and ESR (rho = -0.39); all P < 0.05. VLDL concentrations correlated with CRP (rho = 0.22), ESR (rho = 0.24), disease damage (rho = 0.20), and corticosteroid exposure (rho = 0.29); all P < 0.05. Neither the concentration of lipoprotein subclasses nor particle size was associated with coronary artery atherosclerosis. There were only minor differences in the NMR lipid profiles of patients with SLE and controls. Lipoprotein subclasses were associated with metabolic variables, inflammatory markers, and corticosteroid use but not with coronary artery atherosclerosis in SLE.
KW - Atherosclerosis
KW - Lipids
KW - NMR
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=51549089148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51549089148&partnerID=8YFLogxK
U2 - 10.1007/s10067-008-0890-4
DO - 10.1007/s10067-008-0890-4
M3 - Article
C2 - 18421545
AN - SCOPUS:51549089148
SN - 0770-3198
VL - 27
SP - 1227
EP - 1233
JO - Clinical Rheumatology
JF - Clinical Rheumatology
IS - 10
ER -